NEW YORK, Dec. 4 – Paradigm Genetics has entered a deal to acquire Celera’s AgGen plant genomics and genotyping business in a stock deal valued at $2.1 million, the companies said Tuesday.

Under the terms of the deal, Celera will receive 422,459 Paradigm shares. Paradigm closed at $4.87 in trading on the Nasdaq Monday.

Celera will also share service revenues with Paradigm. Further details and specifics about the revenue sharing plan were not available.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.